AKTX · Akari Therapeutics Plc
$9.29
-0.60 (-6.07%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the "consolidated financial statements") are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$22.05M
Shares
2.29M
Volume · Oct 20
35.12K
Avg daily vol (3M)
61.44K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.29
Open$9.15
Day$9.15–9.72
52W close$3.06–32.80
Avg vol 30d60K
Short int15K · 0.6% float · 1.0d
Short vol53%
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$354,023
Trailing 12 months
Net income (TTM)
−$30.96M
Trailing 12 months
Revenue growth YoY
-39.5%
Year over year
Operating margin
-4,568.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+127.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.6%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+1%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+77%
trailing
YTD return
−20%
this year
Relative strength
+69%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
2 of 10 funds reported for Sep 30 · net +2.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.64% of float · ▲ +35.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
−39%
Y/Y
Free cash flow
$-10.6M
Quant / Vol
risk profile
Volatility
294%
annualized · 1-yr
Max drawdown
−91%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
2 of 10 funds reported for Sep 30 · net +2.4K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.64% of float · ▲ +35.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $9 · 21%
Range high $33
vs 200-day avg +1%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Fair value of AKTX-101 IPR&D asset | $30.3M | the quarter ended March 31, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AKTX
this stock
Akari Therapeutics Plc
|
$22.05M | — | -39.5% | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
11
- % held
- 7.1%
- Reported
- 2 of 10
- Top holder
- MMCAP International Inc.…
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AKTX | +17.6% | -7.6% | +77.3% | -0.1% | -19.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +18.7% | -7.0% | +69.2% | -1.0% | -32.4% |